Frenelle Pharma

Executive Summary

Frenelle Pharma is a US-based biotechnology company focused on drug delivery, leveraging its proprietary long-acting injectable (LAI) platform, Faros™. Founded in 2018 and headquartered in New York, the company aims to improve existing treatments by enabling sustained release of therapeutics, thereby enhancing patient compliance and outcomes. Frenelle's strategy involves creating subsidiary companies that target specific therapeutic areas with high unmet need, such as central nervous system disorders, oncology, and infectious diseases. The Faros platform is designed to be versatile, potentially applicable to a wide range of drug modalities including small molecules, peptides, and biologics. The company is currently in Phase 2 development for its lead candidate, which targets a yet-unspecified indication, and is actively pursuing partnerships to expand its pipeline. Frenelle's business model of incubating and spinning out subsidiaries allows it to de-risk development while maintaining strategic control over the platform technology. The company's focus on long-acting injectables addresses a significant market need, particularly in chronic disease management where frequent dosing can be burdensome. With a growing interest from large pharma in LAI technologies for patient adherence, Frenelle is well-positioned to capture value. However, as an early-stage private company with limited public disclosures, investment carries risk. The upcoming milestones, including Phase 2 data readouts and potential partnership announcements, will be critical in validating the platform and driving valuation.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 clinical trial data readout for lead candidate45% success
• Q2 2027Partnership or licensing deal for Faros platform35% success
• Q1 2027Spin-out of subsidiary in CNS or oncology40% success